PPARG and metabolic disease: Taken together, our data propose pharmacological reduction of LIP expression as an approach to switch the unhealthy metabolic phenotype of obese individuals into a healthy obese phenotype to prevent the development of metabolic disease (possibly together with pharmacologic PPARγ activation).